Publications
Find coverage of the latest original articles on Lupus, focusing on those with data on therapeutic interventions and those that have clinical impact.
October 2021
Baricitinib for Lupus Erythematosus: A Double-Blind, Randomised, Placebo-Controlled, Phase 2 Trial
Lancet 2018;392:222–31
This international Phase 2 study aimed to assess the efficacy and safety of baricitinib, an oral JAK-1 and -2 inhibitor, in patients with SLE who were not adequately controlled despite standard background therapy.
Keywords:
Anifrolumab, an Anti-Interferon-α Receptor Monoclonal Antibody, in Moderate-to-Severe Systemic Lupus Erythematosus
Arthritis Rheumatol 2017;69:376–86
One of the challenges of treating SLE is the limited efficacy and poor tolerability of current therapies.
Keywords:
Long-term Organ Damage Accrual and Safety in Patients with SLE Treated with Belimumab Plus Standard of Care
Lupus 2016;25:699–709
Both active disease and medication toxicity can result in the accrual of long-term organ damage in SLE.
Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus
Arthritis Rheumatol . 2018 Jun;70(6):868-877
This long-term Phase 3 study confirmed the safety and efficacy of belimumab in patients with SLE.